MCID: CTN003
MIFTS: 52

Cutaneous Lupus Erythematosus

Categories: Rare diseases, Immune diseases, Skin diseases

Aliases & Classifications for Cutaneous Lupus Erythematosus

MalaCards integrated aliases for Cutaneous Lupus Erythematosus:

Name: Cutaneous Lupus Erythematosus 12 76 53 37 15
Lupus Erythematosus, Cutaneous 53 73
Lupus Erythematosus Cutaneous 55

Classifications:



External Ids:

Disease Ontology 12 DOID:0050169
KEGG 37 H01595
UMLS 73 C0024137

Summaries for Cutaneous Lupus Erythematosus

Disease Ontology : 12 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight.

MalaCards based summary : Cutaneous Lupus Erythematosus, also known as lupus erythematosus, cutaneous, is related to subacute cutaneous lupus erythematosus and chilblain lupus 1, and has symptoms including exanthema and pruritus. An important gene associated with Cutaneous Lupus Erythematosus is CXCR3 (C-X-C Motif Chemokine Receptor 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Influenza A. The drugs Hydroxychloroquine and Antirheumatic Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Cutaneous Lupus Erythematosus

Diseases in the Cutaneous Lupus Erythematosus family:

Subacute Cutaneous Lupus Erythematosus

Diseases related to Cutaneous Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
# Related Disease Score Top Affiliating Genes
1 subacute cutaneous lupus erythematosus 34.7 EEA1 TNF TRIM21
2 chilblain lupus 1 30.3 MX1 TREX1 TRIM21
3 sialadenitis 30.3 TNF TRIM21
4 lupus erythematosus 30.1 CD40LG TNF TREX1 TRIM21 TROVE2
5 actinic prurigo 29.1 ICAM1 SELE TNF
6 lymphadenitis 29.0 CXCR3 ICAM1 IL18 TNF
7 alopecia areata 28.9 GZMB ICAM1 TNF
8 erythema multiforme 28.6 CXCR3 GZMB ICAM1 TNF
9 psoriasis 28.5 CXCR3 ICAM1 IL18 SELE TNF
10 vasculitis 28.4 CD40LG ICAM1 SELE TNF
11 lichen planus 28.1 CXCR3 GZMB ICAM1 MX1 TNF
12 rheumatoid arthritis 27.9 CD40LG ICAM1 IL18 SELE TNF
13 systemic lupus erythematosus 25.5 CD40LG CXCR3 ICAM1 IL18 SELE TNF
14 lupus erythematosus tumidus 11.7
15 neonatal lupus erythematosus 11.5
16 systemic onset juvenile idiopathic arthritis 10.8 IL18 TNF
17 listeria meningitis 10.7 IL18 TNF
18 stachybotrys chartarum 10.7 IL18 TNF
19 inflammatory bowel disease 3 10.6 IL18 TNF
20 critical limb ischemia 10.6 SELE TNF
21 scleritis 10.6 SELE TNF
22 retinitis pigmentosa 60 10.5 SELE TNF
23 intermediate uveitis 10.5 CXCR3 TNF
24 lichen sclerosus 10.5 GZMB TNF
25 orofacial granulomatosis 10.4 CXCR3 TNF
26 cat-scratch disease 10.4 CD40LG EEA1
27 trench fever 10.4 CD40LG TNF
28 rheumatoid lung disease 10.4 CD40LG TNF
29 bartonellosis 10.4 CD40LG EEA1
30 third-degree atrioventricular block 10.4 TRIM21 TROVE2
31 mycobacterium tuberculosis 1 10.4 CXCR3 IL18 TNF
32 miller fisher syndrome 10.4 CD40LG TNF
33 heart block, congenital 10.4 TRIM21 TROVE2
34 bacterial conjunctivitis 10.4 CD40LG KRT15
35 necrotizing ulcerative gingivitis 10.4 CD40LG IL18
36 rift valley fever 10.3 CD40LG MX1
37 t-cell large granular lymphocyte leukemia 10.3 GZMB IL18
38 schnitzler syndrome 10.3 CD40LG IL18
39 hyperglobulinemic purpura 10.3 CD40LG TRIM21
40 central nervous system vasculitis 10.3 CD40LG TNF
41 osteosclerotic myeloma 10.3 CD40LG TNF
42 facial hemiatrophy 10.2 CD40LG TRIM21
43 rasmussen encephalitis 10.2 GZMB IL18 TNF
44 primary systemic mycosis 10.2 CD40LG TNF
45 acute graft versus host disease 10.2 GZMB IL18 TNF
46 jejunoileitis 10.2 CD40LG TNF
47 dermatomyositis 10.2
48 african tick-bite fever 10.2 CD40LG SELE
49 acute salpingitis 10.2 CD40LG TNF
50 hemophagocytic lymphohistiocytosis 10.2 GZMB IL18 TNF

Graphical network of the top 20 diseases related to Cutaneous Lupus Erythematosus:



Diseases related to Cutaneous Lupus Erythematosus

Symptoms & Phenotypes for Cutaneous Lupus Erythematosus

UMLS symptoms related to Cutaneous Lupus Erythematosus:


exanthema, pruritus

GenomeRNAi Phenotypes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 CD40LG GZMB ICAM1 IL18 MX1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 CD40LG GZMB ICAM1 IL18 MX1 TNF

MGI Mouse Phenotypes related to Cutaneous Lupus Erythematosus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.91 TREX1 TRIM21 CD40LG CXCR3 TROVE2 ICAM1
2 homeostasis/metabolism MP:0005376 9.81 TNF TREX1 TRIM21 CD40LG CXCR3 ICAM1
3 immune system MP:0005387 9.61 TREX1 TRIM21 CD40LG CXCR3 TROVE2 ICAM1
4 integument MP:0010771 9.23 TREX1 TRIM21 CD40LG TROVE2 ICAM1 IL18

Drugs & Therapeutics for Cutaneous Lupus Erythematosus

Drugs for Cutaneous Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 3,Phase 2 118-42-3 3652
2 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
3 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
4 Antimalarials Phase 3,Phase 2
5 Antiparasitic Agents Phase 3,Phase 2
6 Antiprotozoal Agents Phase 3,Phase 2
7 Dermatologic Agents Phase 3,Phase 2,Not Applicable
8 Protective Agents Phase 3,Not Applicable
9 Radiation-Protective Agents Phase 3,Not Applicable
10 Sunscreening Agents Phase 3,Not Applicable
11
Etanercept Approved, Investigational Phase 2 185243-69-0
12
Norflurane Approved, Investigational Phase 2 811-97-2
13
Tacrolimus Approved, Investigational Phase 2,Not Applicable 104987-11-3 445643 439492
14
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 5271565 637568
15
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
16
Tofacitinib Approved, Investigational Phase 1, Phase 2,Early Phase 1 477600-75-2
17
Alitretinoin Approved, Investigational Phase 2 5300-03-8 444795 449171
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
19
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
20
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
21
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
22
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
24
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
25 Antibodies Phase 1, Phase 2,Phase 2,Early Phase 1
26 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2
27 Immunoglobulins Phase 1, Phase 2,Phase 2,Early Phase 1
28 Analgesics Phase 2,Phase 1,Not Applicable
29 Analgesics, Non-Narcotic Phase 2,Phase 1,Not Applicable
30 Anti-Inflammatory Agents Phase 2,Phase 1,Not Applicable
31 Anti-Inflammatory Agents, Non-Steroidal Phase 2,Phase 1,Not Applicable
32 Gastrointestinal Agents Phase 2
33 Immunosuppressive Agents Phase 2,Not Applicable
34 Peripheral Nervous System Agents Phase 2,Phase 1,Not Applicable
35 Calcineurin Inhibitors Phase 2,Not Applicable
36 Phosphodiesterase 4 Inhibitors Phase 1, Phase 2
37 Phosphodiesterase 5 Inhibitors Phase 1, Phase 2
38 Phosphodiesterase Inhibitors Phase 1, Phase 2
39 Angiogenesis Inhibitors Phase 2,Not Applicable
40 Angiogenesis Modulating Agents Phase 2,Not Applicable
41 Anti-Bacterial Agents Phase 2,Not Applicable
42 Vaccines Phase 2
43 Antimetabolites Phase 2
44 Hypolipidemic Agents Phase 2
45 Lipid Regulating Agents Phase 2
46 Micronutrients Phase 2
47 Nicotinic Acids Phase 2
48 Trace Elements Phase 2
49 Vasodilator Agents Phase 2
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
2 Sunscreen RV 2457C in Photoinduced CLE Completed NCT00470912 Phase 3 sunscreen RV 2547C
3 Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Recruiting NCT03178188 Phase 2, Phase 3
4 A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus Recruiting NCT03517722 Phase 3 Placebo;Ustekinumab (approximately 6 mg/kg);Ustekinumab 90 mg
5 Phase Ib Study of SC Milatuzumab in SLE Unknown status NCT01845740 Phase 1, Phase 2 milatuzumab;Placebo
6 The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus Unknown status NCT00797784 Phase 2 etanercept(Enbrel®)
7 Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser Completed NCT00523588 Phase 2
8 Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus Completed NCT01294774 Phase 2 KRP203 - 1.2mg;Placebo to KRP203 - 1.2 mg
9 To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Completed NCT01300208 Phase 2 CC-11050
10 Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE) Completed NCT00317681 Phase 2 Tacrolimus ointment
11 Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Completed NCT01352988 Phase 2 Fumaric acid esters
12 Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients Completed NCT00708916 Phase 1, Phase 2 CC-10004
13 A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus Completed NCT01283139 Phase 2
14 A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus Completed NCT02437890 Phase 2
15 Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions Completed NCT01597050 Phase 2 R932333;Placebo
16 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions Completed NCT00625521 Phase 2 ASF 1096 0.5 % cream applied twice daily;Cream vehicle for ASF 1096 cream applied twice daily
17 Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2) Completed NCT00625157 Phase 2 ASF 1096 0.5 % cream;ASF 1096 placebo cream
18 A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus Completed NCT00001680 Phase 2 Thalidomide
19 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
20 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2 BIIB059;Placebo
21 Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Recruiting NCT03134222 Phase 2 Filgotinib;GS-9876;Filgotinib placebo;GS-9876 placebo
22 Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus Recruiting NCT03260166 Phase 2 nicotinamide
23 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) Recruiting NCT02660944 Phase 2 RSLV-132;Placebo
24 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
25 Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus Recruiting NCT03451422 Phase 1, Phase 2 AMG 592;Placebo
26 An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus Recruiting NCT03252587 Phase 2 BMS-986165
27 A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE) Recruiting NCT02975336 Phase 2 Placebo;M2951;M2951;M2951
28 Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care Recruiting NCT03371251 Phase 1, Phase 2 BOS161721;Placebo
29 Study of Anti-Malarials in Incomplete Lupus Erythematosus Recruiting NCT03030118 Phase 2 Hydroxychloroquine;Placebo Oral Capsule
30 Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Active, not recruiting NCT02656082 Phase 2 Etanercept
31 Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Terminated NCT01407679 Phase 2 Alitretinoin
32 Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Terminated NCT01498406 Phase 2
33 TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment Terminated NCT02711813 Phase 2 TAB08
34 A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus Terminated NCT01466725 Phase 2 CC-930;Placebo
35 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Terminated NCT02265744 Phase 2 BMS-931699;Placebo matching BMS-931699
36 Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva Terminated NCT00308204 Phase 2 Raptiva (efalizumab)
37 A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus Completed NCT01702740 Phase 1 1 mg/kg CNTO 136;4 mg/kg CNTO 136;10 mg/kg CNTO 136;Placebo
38 A Study of NKTR-358 in Participants With Systemic Lupus Erythematosis (SLE) Recruiting NCT03556007 Phase 1 NKTR-358;Placebo
39 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Patients Active, not recruiting NCT02927457 Phase 1 GSK2646264 1%;Placebo
40 Autologous Polyclonal Tregs for Lupus Active, not recruiting NCT02428309 Phase 1
41 A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus Terminated NCT01470313 Phase 1 PD-0360324;Placebo
42 Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Terminated NCT01389895 Phase 1 AMG 557;AMG 557 Placebo
43 Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus Terminated NCT01164917 Phase 1 AMG811;AMG811 Placebo
44 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus Completed NCT01629784 Not Applicable
45 IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus Completed NCT01841619 Early Phase 1 IVIg
46 Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE) Completed NCT00633945 Not Applicable lenalidomide (Revlimid®)
47 Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) Completed NCT01146444 Not Applicable
48 A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Completed NCT02034344
49 Interdisciplinary Study Group of Lupus Erythematosus (ISGLE) Completed NCT00420173
50 A Non-drug Study Profiling Cutaneous Lupus Completed NCT01923415

Search NIH Clinical Center for Cutaneous Lupus Erythematosus

Genetic Tests for Cutaneous Lupus Erythematosus

Anatomical Context for Cutaneous Lupus Erythematosus

MalaCards organs/tissues related to Cutaneous Lupus Erythematosus:

41
Skin, Lung, Heart, Kidney, T Cells, Bone, Breast

Publications for Cutaneous Lupus Erythematosus

Articles related to Cutaneous Lupus Erythematosus:

(show top 50) (show all 764)
# Title Authors Year
1
Subacute cutaneous lupus erythematosus: is clopidogrel a trigger? ( 29327459 )
2018
2
CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study. ( 29728857 )
2018
3
Subacute Cutaneous Lupus Erythematosus Induced by Palbociclib. ( 29307217 )
2018
4
Cutaneous lupus erythematosus: clinico-pathologic correlation. ( 29368845 )
2018
5
Autoimmune Diseases in Patients With Cutaneous Lupus Erythematosus. ( 29801110 )
2018
6
Drug-induced Subacute Cutaneous Lupus Erythematosus Caused by a Topical Beta Blocker - Timolol. ( 29782299 )
2018
7
Cutaneous lupus erythematosus, morphea profunda and psoriasis: A case report. ( 29625815 )
2018
8
Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study. ( 29496481 )
2018
9
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( 28989111 )
2018
10
Subacute cutaneous lupus erythematosus presenting in twins. ( 29436018 )
2018
11
Natural History of Disease Activity and Damage in Patients with Cutaneous Lupus Erythematosus. ( 29969701 )
2018
12
Autoantibody profile and clinical patterns in 619 Italian patients with cutaneous lupus erythematosus. ( 29924416 )
2018
13
Incremental health care services and expenditures associated with depression among individuals with cutaneous lupus erythematosus (CLE). ( 29514557 )
2018
14
The devil's in the dosing: severe drug-induced liver injury in a hydroxychloroquine-naive patient with subacute cutaneous lupus erythematosus and porphyria cutanea tarda. ( 29631513 )
2018
15
Occupational subacute cutaneous lupus erythematosus caused by outdoor work. ( 29603599 )
2018
16
Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity. ( 29349515 )
2018
17
Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. ( 29061479 )
2018
18
Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus. ( 29924233 )
2018
19
Cutaneous lupus erythematosus in dogs: a comprehensive review. ( 29669547 )
2018
20
Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. ( 29760621 )
2018
21
Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. ( 29788808 )
2018
22
Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study. ( 29885269 )
2018
23
Ten-year retrospective clinicohistological study of cutaneous lupus erythematosus in Korea. ( 29423919 )
2018
24
Chronic Cutaneous Lupus Erythematosus in a Blaschkoid Pattern over Face. ( 29692464 )
2018
25
Coexistence of chronic cutaneous lupus erythematosus and frontal fibrosing alopecia. ( 29723351 )
2018
26
Successful treatment of severe subacute cutaneous lupus erythematosus with rituximab in an adolescent. ( 29570834 )
2018
27
Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern United States: The Georgia Lupus Registry. ( 29669194 )
2018
28
An update in drug-induced subacute cutaneous lupus erythematosus. ( 28329511 )
2017
29
Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. ( 28480635 )
2017
30
Pigmented macular variant of chronic cutaneous lupus erythematosus: an under-recognized subset in dark skin. ( 28590034 )
2017
31
Histologic features of chronic cutaneous lupus erythematosus of the scalp using horizontal sectioning: Emphasis on follicular findings. ( 28624120 )
2017
32
Subacute cutaneous lupus erythematosus - paraneoplastic to gastric adenocarcinoma? ( 28421344 )
2017
33
Results of lumbar puncture, CT and MRI in a case of quinacrine-induced psychosis involving a patient with cutaneous lupus erythematosus. ( 28540035 )
2017
34
The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. ( 28711090 )
2017
35
Subacute cutaneous lupus erythematosus induced by masitinib. ( 28940367 )
2017
36
Cutaneous lupus erythematosus and the risk of deep venous thrombosis and pulmonary embolism: A Danish nationwide cohort study. ( 28618892 )
2017
37
Chronic cutaneous lupus erythematosus presenting as atypical acneiform and comedonal plaque: case report and literature review. ( 28857716 )
2017
38
Dyschromatosis symmetrica hereditaria with cutaneous lupus erythematosus and hyperthyroidism. ( 28496371 )
2017
39
Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease Associations, Treatments, and Outcomes in a Series of 90A Patients at Mayo Clinic, 1996-2011. ( 28185656 )
2017
40
TWEAK/Fn14 Activation Participates in Ro52-Mediated Photosensitization in Cutaneous Lupus Erythematosus. ( 28620393 )
2017
41
Rowell's Syndrome or subacute cutaneous lupus erythematosus? ( 27978611 )
2017
42
Imiquimod-induced cutaneous lupus erythematosus with antinuclear antibodies showing a homogenous pattern. ( 28616880 )
2017
43
Cutaneous Lupus Erythematosus Presenting as Frontal Fibrosing Alopecia: Report of 2 Patients. ( 29177150 )
2017
44
Topical drug-induced subacute cutaneous lupus erythematosus isolated to the hands. ( 28331627 )
2017
45
The deposition of anti-DNA IgG contributes to the development of cutaneous lupus erythematosus. ( 28899632 )
2017
46
The Histopathological Spectrum of Pseudolymphomatous Infiltrates in Cutaneous Lupus Erythematosus. ( 28654469 )
2017
47
Bizarre appearance of chronic cutaneous lupus erythematosus of face mimicking factitial dermatitis. ( 29224226 )
2017
48
Chronic cutaneous lupus erythematosus revealed by unilateral eyelid oedema. ( 28943504 )
2017
49
A Cutaneous Lupus Erythematosus-Like Eruption Induced by Hydroxyurea. ( 27813209 )
2017
50
Nuclear proteins and apoptotic bodies are found in the lupus band of patients with cutaneous lupus erythematosus. ( 28842330 )
2017

Variations for Cutaneous Lupus Erythematosus

Expression for Cutaneous Lupus Erythematosus

Search GEO for disease gene expression data for Cutaneous Lupus Erythematosus.

Pathways for Cutaneous Lupus Erythematosus

Pathways related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 CD40LG ICAM1 IL18 MX1 TNF TRIM21
2
Show member pathways
12.57 ICAM1 IL18 MX1 TNF
3
Show member pathways
12.51 CD40LG GZMB ICAM1 IL18 TNF
4 12.03 CD40LG GZMB TNF
5 12.01 EEA1 IL18 TNF
6 11.88 CD40LG ICAM1 SELE
7 11.86 ICAM1 SELE TNF
8 11.74 ICAM1 IL18 TNF
9 11.69 ICAM1 SELE TNF
10 11.63 ICAM1 SELE TNF
11 11.59 CD40LG ICAM1 TNF
12 11.53 ICAM1 IL18 TNF
13 11.46 CXCR3 GZMB IL18 TNF
14
Show member pathways
11.26 CD40LG ICAM1 SELE TNF
15 11.19 ICAM1 IL18 TNF
16 10.97 ICAM1 IL18
17 10.9 IL18 TNF
18 10.8 ICAM1 IL18 SELE TNF
19 10.73 ICAM1 TNF
20 10.71 CD40LG ICAM1 IL18 SELE TNF

GO Terms for Cutaneous Lupus Erythematosus

Cellular components related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD40LG CXCR3 ICAM1 TNF

Biological processes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.58 CD40LG ICAM1 TNF
2 negative regulation of myoblast differentiation GO:0045662 9.46 IL18 TNF
3 natural killer cell mediated cytotoxicity GO:0042267 9.43 GZMB IL18
4 regulation of type I interferon production GO:0032479 9.37 TREX1 TRIM21
5 inflammatory response GO:0006954 9.35 CD40LG CXCR3 IL18 SELE TNF
6 leukocyte tethering or rolling GO:0050901 9.32 SELE TNF
7 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.26 ICAM1 TNF
8 regulation of immunoglobulin secretion GO:0051023 9.16 CD40LG TNF
9 leukocyte cell-cell adhesion GO:0007159 8.8 CD40LG ICAM1 SELE

Sources for Cutaneous Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....